Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
Retained Earnings
Gilead Sciences Inc
Retained Earnings Peer Comparison
Competitive Retained Earnings Analysis
Latest Figures & CAGR of Competitors
Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gilead Sciences Inc
NASDAQ:GILD
|
Retained Earnings
$10.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
|
Abbvie Inc
NYSE:ABBV
|
Retained Earnings
-$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Retained Earnings
-$27.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-15%
|
|
Moderna Inc
NASDAQ:MRNA
|
Retained Earnings
$12.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Retained Earnings
$11.2B
|
CAGR 3-Years
95%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Retained Earnings
$28B
|
CAGR 3-Years
33%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
See Also
What is Gilead Sciences Inc's Retained Earnings?
Retained Earnings
10.7B
USD
Based on the financial report for Mar 31, 2024, Gilead Sciences Inc's Retained Earnings amounts to 10.7B USD.
What is Gilead Sciences Inc's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
3%
Over the last year, the Retained Earnings growth was -30%. The average annual Retained Earnings growth rates for Gilead Sciences Inc have been -10% over the past three years , -11% over the past five years , and 3% over the past ten years .